https://ipharmag.com/article/zipalertinib-egfr-exon20-lung-cancer-phase3 iPharmag en 2026-08-14T04:39:01+00:00 Taiho and Cullinan’s Lung Cancer Drug Aces a Phase 3 Trial, Heating Up a Crowded Race https://ipharmag.com/article/thermo-michael-j-fox-parkinsons-proteomics iPharmag en 2026-08-14T04:39:01+00:00 Thermo and the Michael J. Fox Foundation Map 5,500 Samples to Hunt Parkinson’s Biomarkers https://ipharmag.com/article/ptc-sangamo-fabry-gene-therapy-acquisition iPharmag en 2026-08-14T04:39:01+00:00 PTC Buys a Fabry Disease Gene Therapy From Bankrupt Sangamo for Up to $211M https://ipharmag.com/article/omega-fatty-acids-nk-cells-cancer-lrp5 iPharmag en 2026-08-14T04:39:01+00:00 Could Omega Fatty Acids Blunt an Immune Cell’s Cancer Defense? A Mouse Study Raises the Question https://ipharmag.com/article/fda-approves-zenbexus-iberdomide-celmod-myeloma iPharmag en 2026-08-14T04:39:01+00:00 FDA Approves Bristol Myers’ Zenbexus, the First of a New Class of Myeloma Drugs